02 赛诺菲和葛兰素史克为延迟推出的新冠疫苗申请监管批准

Sanofi and GlaxoSmithKline will apply for regulatory approval of their long-awaited Covid-19 vaccine as a primary jab and booster, after reporting an overall efficacy rate of 57.9 per cent.

赛诺菲(Sanofi)和葛兰素史克(GlaxoSmithKline)将申请监管机构批准它们期待已久的新冠疫苗作为基础剂和加强针，此前两家公司报告的总有效性为57.9%。

The two large vaccine makers have lagged behind in the race to develop a Covid shot after a dosing mistake that forced the French drugmaker and its UK partner to redo an earlier trial. This delay meant the phase 3 trial was conducted while variants were circulating that could have reduced the efficacy of the jab.

这两家大型疫苗制造商在研发新冠疫苗的竞赛中落后，此前的剂量错误迫使这家法国制药商及其英国合作伙伴重新进行早期试验。这一延迟意味着III期试验是在可能降低疫苗有效性的变种流行的情况下进行的。

The late-stage trial showed the vaccine was 100 per cent effective against severe disease and hospitalisation and 75 per cent effective against moderate to severe Covid. An early analysis suggests it could be more effective against disease caused by the Delta variant.

后期试验表明，该疫苗对预防新冠重症和住院风险的有效性达100%，在预防中度或重症风险方面有效性达75%。一项早期的分析表明，它对预防由Delta变种引发症状更有效。